Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biofrontera Inc

0.7000
-0.0299-4.10%
Volume:66.00K
Turnover:46.76K
Market Cap:6.21M
PE:-0.22
High:0.7313
Open:0.7200
Low:0.6800
Close:0.7299
Loading ...

Biofrontera AG’s Earnings Call Highlights Growth and Strategic Advances

TIPRANKS
·
24 Apr

Biofrontera AG Prepares to Release 2024 Financial Report

TIPRANKS
·
17 Apr

Biofrontera AG Reports 2024 Financial Results and Strategic Growth Plans

TIPRANKS
·
15 Apr

Biofrontera AG Meets 2024 Forecasts and Outlines 2025 Financial Expectations

TIPRANKS
·
15 Apr

Biofrontera’s Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results

TIPRANKS
·
25 Mar

Biofrontera Inc. Reports Record Sales and Strategic Advances

TIPRANKS
·
25 Mar

Biofrontera Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
22 Mar

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

GuruFocus.com
·
22 Mar

Q4 2024 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents
·
22 Mar

Biofrontera Inc. Reports Record Revenue Growth in 2024

TIPRANKS
·
22 Mar

Biofrontera Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
21 Mar

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

THOMSON REUTERS
·
21 Mar

Biofrontera Q4 Revenue USD 12.6 Million

THOMSON REUTERS
·
21 Mar

Biofrontera Q4 Adjusted Ebitda USD -1.4 Million

THOMSON REUTERS
·
21 Mar

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
21 Mar

Biofrontera FY 2024 GAAP EPS $(3.22) May Not Be Comparable To $(0.85) Estimate, Sales $37.32M Miss $47.06M Estimate

Benzinga
·
21 Mar

Biofrontera Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
19 Mar

Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses

MT Newswires Live
·
18 Mar

Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk

GlobeNewswire
·
18 Mar

Biofrontera Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
12 Mar